Christopher Oakes, PhD

The Role of EGR in establishing a malignant epigenetic program of therapy resistance in CLL

Modification of gene structure constitutes a fundamental way healthy cells are reprogrammed into leukemia and gain therapeutic resistance. We will uncover how modifications associated with aggressive disease and relapse are created by reengineering normal cells. This will further our knowledge of relapse risk, detection, and how to circumvent therapy resistance.